Loading...
XSHE
002294
Market cap8.39bUSD
Jun 16, Last price  
53.86CNY
1D
-2.02%
1Q
76.19%
Jan 2017
84.20%
IPO
138.00%
Name

Shenzhen Salubris Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
99.81
P/S
14.97
EPS
0.54
Div Yield, %
0.93%
Shrs. gr., 5y
1.33%
Rev. gr., 5y
-2.14%
Revenues
4.01b
+19.22%
203,143,936349,434,747527,169,507849,597,6711,297,767,1161,474,884,5261,828,881,5332,327,483,5052,882,644,6043,477,692,8683,833,490,2234,153,776,6094,651,876,1994,470,465,9802,738,562,2963,058,392,0413,482,011,3783,365,343,3424,012,231,593
Net income
602m
+3.71%
34,238,76973,137,727116,941,762215,747,086355,314,294405,249,376635,167,523830,416,5811,042,297,0821,265,920,0251,396,414,1501,451,887,2581,458,223,270715,201,07660,864,986533,726,576637,091,085580,066,240601,569,140
CFO
1.19b
+36.38%
12,004,69552,753,54377,893,191134,282,021186,649,350272,318,579521,213,683668,521,964982,249,1461,056,028,8261,434,812,0031,457,722,4261,340,663,5161,506,644,7991,374,329,0191,184,978,525970,804,863869,792,2661,186,258,420
Dividend
Jun 19, 20240.5 CNY/sh

Profile

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.
URL
http://www.salubris.cn/
IPO date
Sep 10, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,012,232
19.22%
3,365,343
-3.35%
3,482,011
13.85%
Cost of revenue
2,580,667
2,151,327
2,684,159
Unusual Expense (Income)
NOPBT
1,431,564
1,214,016
797,852
NOPBT Margin
35.68%
36.07%
22.91%
Operating Taxes
27,361
60,932
79,507
Tax Rate
1.91%
5.02%
9.97%
NOPAT
1,404,204
1,153,084
718,345
Net income
601,569
3.71%
580,066
-8.95%
637,091
19.37%
Dividends
(545,680)
(437,564)
Dividend yield
1.50%
1.21%
Proceeds from repurchase of equity
26,195
BB yield
-0.07%
Debt
Debt current
120,000
40,000
188,651
Long-term debt
8,350
25,077
39,165
Deferred revenue
142,038
84,114
98,535
Other long-term liabilities
433,136
416,474
29,641
Net debt
(2,202,931)
(3,839,098)
(3,166,797)
Cash flow
Cash from operating activities
1,186,258
869,792
970,805
CAPEX
(670,999)
Cash from investing activities
(1,401,139)
Cash from financing activities
121,841
(705,535)
FCF
564,922
1,154,072
717,677
Balance
Cash
1,859,269
2,203,541
2,998,829
Long term investments
472,013
1,700,634
395,784
Excess cash
2,130,670
3,735,908
3,220,512
Stockholders' equity
6,248,304
6,823,410
6,744,581
Invested Capital
7,320,995
4,872,645
5,023,565
ROIC
23.03%
23.30%
15.16%
ROCE
15.11%
14.08%
9.65%
EV
Common stock shares outstanding
1,114,017
1,115,512
1,098,433
Price
30.93
-5.30%
32.66
-0.58%
32.85
20.24%
Market cap
34,456,544
-5.42%
36,432,622
0.97%
36,083,521
23.73%
EV
32,293,783
32,629,957
32,952,536
EBITDA
1,807,796
1,559,622
1,118,010
EV/EBITDA
17.86
20.92
29.47
Interest
16,174
17,373
12,539
Interest/NOPBT
1.13%
1.43%
1.57%